IPF Weekly Update

ChatGPTを活用して業務のAI化を進めています。プロンプトエンジニアリングの専門家です！と、名乗れるレベルではありませんが、かなり色々使いこなしてきています。この１年、病気で失われた能力は、別な能力を発達させる、進化することで生き残っていこうと思います。

<><><>

23/08/12

[PDF] The Impact of Integrated Palliative Care on Survival in Idiopathic Pulmonary Fibrosis: A Retrospective Multicenter Comparison

J Lu-Song, JA Bakal, S Younus, O Moran-Mendoza… - American Journal of …, 2023

… -world cohort of patients with idiopathicpulmonary fibrosis, examines the predictors of survival … Results: 298 patients with idiopathicpulmonary fibrosis were enrolled from 3 interstitial lung … (.37-.85)] reduced the risk of death in our …

特発性肺線維症の生存に対する統合緩和ケアの影響：遡及的多施設比較

CALIPER-derived parameters for outcome prediction in idiopathic pulmonary fibrosis

C Romei - European Radiology, 2023

… a diagnostic and prognostic tool in idiopathicpulmonary fibrosis (IPF) is well recognized, as … aiding the radiologist in the diagnosis of IPFand assessment of prognosis and disease … function tests (PFTs) in patients with IPF. The review …

特発性肺線維症の転帰予測のためのCALIPER由来のパラメータ

R Mohamed - 2023

… Idiopathic pulmonary fibrosis (IPF) remains challenging due to the remarkable heterogeneity of the disease prognosis. Therefore, developing reliable prognostic tools is of utmost importance in IPF … cohort study including 152 patients with IPF …

特発性肺線維症患者の健康関連の生活の質と疾患の重症度

[PDF] Bioinformatic analyses and integrated machine learning reveal the role of lactate, a metabolic driver of the immune landscape, serves in idiopathic pulmonary fibrosis

C Chen, S Zhang, G Han, T Yang - 2023

… Background: The development and progression of idiopathic pulmonary brosis (IPF) are signi cantly in uenced by altered lactate … prognosis, and immune environment of IPFpatients. Methods: Transcriptome data of PBMC samples with IPF and lactate …

バイオインフォマティクス分析と統合された機械学習により、特発性肺線維症における免疫環境の代謝ドライバーである乳酸の役割が明らかに

[HTML] Alvespimycin Exhibits Potential Anti-TGF-β Signaling in the Setting of a Proteasome Activator in Rats with Bleomycin-Induced Pulmonary Fibrosis: A Promising Novel …

OA Mohammed, MA Abdel-Reheim, LA Saleh… - Pharmaceuticals, 2023

… Idiopathic pulmonary fibrosis (IPF) is an irreversible and life-threatening lung disease of … Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease that causes scar tissue (… Currently, there is no cure for IPF, and lung …

アルベスピマイシンは、ブレオマイシン誘発性肺線維症のラットにおけるプロテアソーム活性化因子の設定において潜在的な抗TGF-βシグナル伝達を示す：有望な新規アプローチ

[HTML] Molecular mechanisms and treatment responses of pulmonary fibrosis in severe COVID-19

EJ Kooistra, K Dahm, AE van Herwaarden, J Gerretsen… - Respiratory Research, 2023

… cohort of patients with idiopathic pulmonaryfibrosis (IPF, Fig. 2a) [30]. Four-year survival of IPF patients who showed enrichment of the genes in each module was compared to outcome of patients who exhibited no enrichment. Strikingly, survival of …

重症COVID-19における肺線維症の分子機構と治療反応

Increased Lipocalin-2 expression in pulmonary inflammation and fibrosis

AD Galaris, D Fanidis, E Tsitoura, P Kanellopoulou… - Frontiers in Medicine

… Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive interstitial lung disease with dismal prognosis. The underlying pathogenic … tissue of IPF patients negatively correlating with respiratory functions, as also shown for BALF LCN2 …

肺の炎症および線維症におけるリポカリン-2発現の増加

[PDF] A Review: The Potential Involvement of Growth Arrest-Specific 6 and Its Receptors in the Pathogenesis of Lung Damage and in Coronavirus Disease 2019

D Apostolo, LL Ferreira, A Di Tizio, B Ruaro, F Patrucco… - Microorganisms, 2023

… be drawn with other fibrotic diseases, such as idiopathic pulmonary fibrosis. Due to the still limited number of scientific … Pulmonaryfibrosis is a subgroup of interstitial lung diseases (ILD), that includes a variety of parenchymal lung disorders [28] …

総説：肺損傷の病因とコロナウイルス感染症2019における成長停止特異的6とその受容体の潜在的な関与の可能性

23/08/10

[PDF] Idiopathic Pulmonary Fibrosis in a Young Adult: A Rare Presentation and Management Challenges

S Saeed, N Mohammed, N Maktabijahromi, C Ekhator… - Cureus, 2023

… This case study presents a rare occurrence of IPF in a healthy 26-year-old male. He experienced dyspnea, a dry cough, and fatigue for … on a rare occurrence of idiopathicpulmonary fibrosis (IPF) in a young adult, underscoring the significance of …

若年成人における特発性肺線維症：まれな症状と管理上の課題

Design, Development, and In Vitro Characterization of Pirfenidone-Loaded Biodegradable Nanoparticles for Idiopathic Pulmonary Fibrosis

KR Dudhat, HV Patel, DD Mori - Journal of Pharmaceutical Innovation, 2023

… IPF is the most prevalent kind of idiopathicinterstitial lung disease. IPF is a fatal disease in which the uncontrolled deposition of the extracellular … The prevalence of IPF has been reported to range between 10 and 60 cases per 100,000 in the USA …

特発性肺線維症に対するピルフェニドン担持生分解性ナノ粒子の設計、開発、およびin vitro特性評価

Uncomfortable Truths About Data, Justice, and Idiopathic Pulmonary Fibrosis in the Veterans Health Administration

BW Locke, SJ Callahan - CHEST, 2023

The 2014 approvals of pirfenidone and nintedanib for use in idiopathic pulmonaryfibrosis (IPF) by the US Food and Drug Administration were notable in the acceptance of an unproven surrogate end point: decrease in the rate of FVC decline …

退役軍人保健局のデータ、正義、特発性肺線維症に関する不快な真実

AM Cartron, TH Nguyen, YS Roh, MM Kwatra…

… note, leflunomide and low-dose MTX, two disease- modifying anti-rheumatic drugs, have been shown to be effective for patients with severe AD and adults with late-onset AD and idiopathic eczema respec- tively.16,17 Although the exact mechanism of …

セタナキシブは、特発性肺線維症および糖尿病性腎疾患を対象とした研究者主導の試験で評価されている。

Do Comorbidities Cause IPF?

OC Leavy - CHEST, 2023

… Idiopathic pulmonary fibrosis (IPF) is a devastating disease in which irreversible scarring of the lungs occurs. IPF tends to be diagnosed in older men, and … use MR to investigate whether given comorbidities of IPF have a causal relationship with IPF …

[PDF] An alternative in vitro model considering cell-cell interactions in fiber-induced

J Pantzke, J Pantzke, S Offer, J Pantzke, CX EJ… - Toxicology Mechanisms and …

… Until to date, there is no cure for pulmonaryfibrosis and the only treatment is to ease the … In such cases it is referred to idiopathicpulmonary fibrosis (IPF). It is estimated that the latter … evidences for a direct relationship between the …

合併症はIPFの原因になるのか？

Development of a biomimetic Alveolus-on-chip to model the physiological alveolar barrier by supporting multicellular culture and air-liquid interface implementation.

MG De Pasquale - 2023

… For this reason, studying the role of alveolar-capillary barrier in the pulmonary homeostasis plays a fundamental role to understand the pathophysiology of diseases associated with this barrier, such as the asthma, Idiopathicpulmonary …

多細胞培養と気液界面の実装をサポートすることにより、生理学的肺胞関門をモデル化する生体模倣肺胞オンチップの開発。

23/08/08

[PDF] I-PreFer study: a questionnaire to explore patient, caregiver and pulmonologist preferences of idiopathic pulmonary fibrosis treatment options

M Hollmen, T Bromilow, AB Smith, S Mealing, D Lewis… - Patient Preference and …, 2023

… Idiopathic Pulmonary Fibrosis (IPF) is a rare disease that causes shortness of breath, dry cough, and tiredness. While there is no cure for IPF, current therapeutic treatments aim to slow lung degeneration while managing side effects. There is little …

I-PreFer研究：特発性肺線維症の治療選択肢について、患者、介護者、呼吸器科医の好みを調査するためのアンケート

Idiopathic Pulmonary Fibrosis Molecular Substrates Revealed by Competing Endogenous RNA Regulatory Networks

MF Kircali, B Turanli - OMICS: A Journal of Integrative Biology, 2023

… Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic disease of the lung with poor prognosis. Fibrosis results from … IPF. In addition, the molecular leads reported herein might inform future innovations in diagnostics and …

競合する内因性RNA制御ネットワークによって明らかにされた特発性肺線維症の分子基質

[HTML] Real life data on nintedanib safety: idiopathic pulmonary fibrosis versus systemic sclerosis-interstitial lung disease and strategies adopted to manage adverse effects

M Di Battista, L Tavanti, F Pistelli, L Carrozzi, M Da Rio… - Inflammopharmacology, 2023

… slow the progression of idiopathicpulmonary fibrosis (IPF) and systemic sclerosis-related interstitial lung disease (SSc-ILD). NIN can frequently cause gastrointestinal adverse effects. We aimed to investigate the NIN safety profile in a real life setting, comparing …

ニンテダニブの安全性に関する実際のデータ：特発性肺線維症と全身性硬化症 - 間質性肺疾患、および副作用を管理するために採用された戦略

Racial and ethnic disparities in antifibrotic therapy in idiopathic pulmonary fibrosis.

J Zhao, J Fares, G George, A Maheu, G Loizidis… - Respirology (Carlton, Vic.), 2023

… and ethnicity influence treatment of idiopathicpulmonary fibrosis. … IPF patients had lower antifibrotic use compared to White, Hispanic and Asian patients. Our findings suggest that urgent action is needed to understand the reason why racial …

特発性肺線維症における抗線維化療法における人種的および民族的格差。

[HTML] Impact of age and telomere length on circulating T cells and rejection risk after lung transplantation for idiopathic pulmonary fibrosis

ME Snyder, MR Anderson, LJ Benvenuto, RM Sutton… - The Journal of Heart and Lung …

… recipients with idiopathic pulmonaryfibrosis and short telomere length with an age-related difference in T cell phenotype and rejection burden compared to those with normal telomere length. These results suggest that the preserved risk of rejection in those …

特発性肺線維症に対する肺移植後の循環T細胞と拒絶リスクに対する年齢とテロメア長の影響

Reassessing the association of MUC5B with survival in idiopathic pulmonary fibrosis.

S Cai, RJ Allen, LV Wain, F Dudbridge - Annals of Human Genetics, 2023

A variant in the mucin 5B gene (MUC5B) is strongly associated with the risk of idiopathicpulmonary fibrosis. However, the same variant is associated with increased survival time. Previous work suggested that this may be explained by …

特発性肺線維症における生存とMUC5Bの関連性の再評価。

[HTML] A systematic review of the research progress of traditional Chinese medicine against pulmonary fibrosis: from a pharmacological perspective

S Qin, P Tan, J Xie, Y Zhou, J Zhao - Chinese Medicine, 2023

… idiopathic pulmonary fibrosis (abbreviated as IPF), cystic fibrosis, and interstitial pneumonia with autoimmune features, among which IPF … The mortality rate of IPF is high, and more than half of patients with IPF who were hospitalized for acute …

肺線維症に対する伝統的な中国医学の研究進歩の系統的レビュー：薬理学的観点から

[PDF] Local Delivery of Bcar3 siRNA by Nano-Self-Assembly for Treating Pulmonary Fibrosis via Blocking the Interaction of Macrophages and Fibroblasts

C Zeng, Q Wang, C Wang, Q Zhou, X Fu, J Yu, W Xiong… - 2023

… Idiopathic pulmonary brosis (IPF) is a progressive and inevitably fatal interstitial lung disease that mainly manifests as exertional dyspnea … Therefore, developing an effective and safe therapeutic strategy for IPF is urgently needed. In general, IPF …

マクロファージと線維芽細胞の相互作用を遮断することによる肺線維症の治療のためのナノ自己集合によるBcar3 siRNAの局所送達

[PDF] PRDX4 regulates AMs cell activity through the AKT/NF-κB pathway to inhibit the progress of pulmonary fibrosis

J wei Zhou, Z Liu, Y Liu, J Guo, X Yang, Y Li, Y Bai… - 2023

… Idiopathic pulmonary brosis (IPF) is a fatal disease that leads to severe lung brosis, and … mechanisms of the potential therapeutic target PRDX4 in idiopathic pulmonary brosis (IPF). … the progression of IPF, we downloaded single-cell …

PRDX4はAKT/NF-κB経路を介してAM細胞の活性を調節し、肺線維症の進行を阻害する